Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07269236

Prospective Real-World Study of Multimodal AI

This project proposes to collect prospective multimodal data-such as pathology, imaging, and clinical information-and to perform integrative analyses. AI technologies can offer novel solutions for disease classification, tumor grading, histological subtyping, molecular subtyping, selection of chemotherapy regimens, risk stratification, treatment response prediction, report generation, and intelligent question-answering. This research provides important support for precision medicine and individualized treatment and has significant theoretical and practical implications. Conducting a prospective randomized controlled study better aligns with clinical application requirements and can accelerate the comprehensive deployment of AI systems.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Pancancer

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older.
  • Patients with available digitized pathology slides, radiological imaging, and corresponding clinical data.

Exclusion criteria

1.Patients with missing data or specimens not meeting quality control requirements for analysis.

Treatment and study plan

Primary outcomes

  1. Area under ROC curve (AUC)

    Time frame: Diagnostic evaluation will be performed within 1 week when the WSIs or CT are obtained

    Area under the curve

Secondary outcomes

  1. Specificity

    Time frame: Diagnostic evaluation will be performed within 1 week when the WSIs or CT are obtained

    The true negative rate (TNR) of the diagnostic platform, which is the ratio between the number of negative individuals correctly categorized by platform and the total number of actual negative individuals (%).

  2. Sensitivity

    Time frame: Diagnostic evaluation will be performed within 1 week when the WSIs or CT are obtained

    The true positive rate (TPR) of the diagnostic platform, which is the ratio between the number of positive individuals correctly categorized by platform and the total number of actual positive individuals (%).

Sponsors and collaborators

Lead sponsor

Nanfang Hospital, Southern Medical University

Other

Registry information

Official study title

Prospective Real-World Study of a Multimodal Artificial Intelligence Model Across Disease Types

Important dates

Study start
2025
Primary completion
2030
Study completion
2030
First posted
Dec 8, 2025
Registry last updated
Dec 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.